PMID- 7514466
OWN - NLM
STAT- MEDLINE
DCOM- 19940617
LR  - 20191031
IS  - 0169-6009 (Print)
IS  - 0169-6009 (Linking)
VI  - 24
IP  - 1
DP  - 1994 Jan
TI  - Circulating levels of insulin-like growth factor-I and -II, and IGF-binding 
      protein-3 in inflammation and after parathyroid hormone infusion.
PG  - 25-31
AB  - In order to assess if the anabolic action of PTH is related to changes in 
      circulating levels of insulin-like growth factor-I and -II (IGF-I and -II), and 
      IGF binding protein 3 (IGFBP-3), 24 h of PTH infusion was performed in healthy 
      women and in patients with rheumatoid arthritis (RA), a state where both bone 
      metabolism and PTH secretion is influenced by the inflammatory activity. The 
      patients with RA had lower basal levels of both IGF-I and -II than the healthy 
      controls (P < 0.05). In neither group did the IGFs change after 24 h of PTH 
      administration, while IGFBP-3 was significantly increased in the healthy controls 
      (4600 +/- 1200 to 5750 +/- 2200 micrograms/l, P < 0.05). IGFBP-3 was not affected 
      by PTH infusion in patients with RA when the disease had high activity, but when 
      inflammation had subsided they responded with a similar increase in IGFBP-3 as 
      the control group and basal IGF-I and -II levels were normalised. Since IGFBP-3 
      can enhance the anabolic action of IGF-I, increased IGFBP-3 levels after PTH 
      infusion may reflect a mechanism by which PTH is anabolic for bone. Inflammation 
      may inhibit bone formation via decreased serum levels of IGFs and blocked IGFBP-3 
      response to PTH.
FAU - Johansson, A G
AU  - Johansson AG
AD  - Department of Internal Medicine, University Hospital, Uppsala, Sweden.
FAU - Baylink, D J
AU  - Baylink DJ
FAU - af Ekenstam, E
AU  - af Ekenstam E
FAU - Lindh, E
AU  - Lindh E
FAU - Mohan, S
AU  - Mohan S
FAU - Ljunghall, S
AU  - Ljunghall S
LA  - eng
GR  - AR31062/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Ireland
TA  - Bone Miner
JT  - Bone and mineral
JID - 8610542
RN  - 0 (Carrier Proteins)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 0 (Parathyroid Hormone)
RN  - 0 (Peptide Fragments)
RN  - 0 (parathyroid hormone (1-38))
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*blood
MH  - Bone and Bones/drug effects/metabolism
MH  - Calcium/blood
MH  - Carrier Proteins/*blood
MH  - Female
MH  - Humans
MH  - Infusion Pumps
MH  - Insulin-Like Growth Factor Binding Proteins
MH  - Insulin-Like Growth Factor I/*metabolism
MH  - Insulin-Like Growth Factor II/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Parathyroid Hormone/administration & dosage/*pharmacology
MH  - Peptide Fragments/administration & dosage/*pharmacology
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1016/s0169-6009(08)80128-6 [doi]
PST - ppublish
SO  - Bone Miner. 1994 Jan;24(1):25-31. doi: 10.1016/s0169-6009(08)80128-6.